Educational Panel : Funding Cures: Prioritizing Policy Barriers to Amortization of Therapeutic Spending

The tradition of health systems paying for biopharma treatments by the dose gets strained when confronted by the latest therapeutic technologies that may offer multi-year benefits or lifetime relief from disease per a single administration of a highly customized therapy.  Finding analogous methods of matching payment schedules to long-duration benefits, while covering up-front costs, shows how unprepared organizations are for the era of delivering access to gene therapies and other potential cures.  This session will consider market-based options and identify relevant policy barriers to experimenting with amortization models and other techniques for funding non-traditional treatments that could greatly improve or extend patients’ lives.


Moderator: Brady Huggett, Business Editor, Nature Biotechnology


Ted Haack, Vice President, LatticePoint Consulting

Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital

Michael B. Weiss, Partner, Cahill Gordon & Reindel LLP

Michael J. Werner, Partner, Holland & Knight LLP, Co-Founder & Senior Policy Counsel, Alliance for Regenerative Medicine